Pathway for patients with suspected HPB Cancer Inter Provider Transfer

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Karen Pocock Skin Cancer Clinical Nurse Specialist
This presentation will ‘walk’ you through the pathway and guide you on how to use this tool.
A Case Study GP Masterclass Catherine Dale, RN, BSc Cancer Care
Merseyside and Cheshire Cancer Network HEPATO BILIARY MULTIDISCIPLINIARY TEAM MEETING Referral to Specialist HPB (Liver) MDT, University Hospital, Aintree,
Prostate Cancer Support Federation Charity Nº: We have no national screening programme for the most common cancer in men and the only test we.
A Review of Referrals for Suspected Testicular Malignancy Mr Jonathan Harikrishnan ST3 Urology.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Acute Oncology Service (AOS) Monday – Friday 8am – 4pm Bleep: 946 T: x5726 F: Dr Nicola Beech Dr Jillian Noble Dr Susannah.
Breast cancer patient pathway
18 Weeks Referral To Treatment Waiting Times Standard
BTS statement on malignant mesothelioma in the UK, 2007 Thorax 2007 Presentation: R3 黃志宇.
Organized Diagnostic Assessment Demonstration Projects Organized Diagnostic Assessment Demonstration Projects Grand River Regional Diagnostic Assessment.
PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.
Acute Oncology Dr Nicola Storey.
Gynaecology MDT Coordinator
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.
Summary The National Clinical Pathway represents a pathway that is achievable now, requiring no extra resources but reliant on appropriate logistics. The.
[Name of Presenter] [Details of patient e.g. initials, hospital number etc.] [Date of meeting]
National Optimal Clinical Pathway for suspected and confirmed lung cancer: Referral to treatment Note: this was previously circulated for discussion as.
NICE GUIDELINES February 2016
National Clinical Pathway for suspected and confirmed lung cancer:
2 November John Childs and Deborah Woodley
Walking alongside you, against the tide
Challenges of Rare Cancers…
Melanoma Staging an update
Oesophago–Gastric Cancer
Velindre NHS Trust June 10th 2011
‘Piloting change’ report on the Multi Disciplinary Diagnostic centre
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
Paediatric Orthopaedic MSK Pathways Pamela Holland
NICE Guidance – Service delivery for patients with Sarcomas
Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Oesophago–Gastric Cancer
Recognition and Referral of Suspected cancer NICE NG12 – 2Week Wait
Mr Michael Thomas, Colorectal Cancer SSG, 27th June 2018
Pathway for patients with suspected Breast Cancer
Six stage journey When diagnosed with a brain tumour.
18 Weeks Referral To Treatment Waiting Times Standard
Katie’s story: Advanced colorectal cancer
Cancer Waiting Times Standards
Pathway for patients with suspected Skin Cancer
Pathway for patients with suspected Upper GI (OG) Cancer
Neuro Oncology Therapy Update
Lung Cancer Pathways: Interim Report
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Early Diagnosis Diagnostics Cancer Waits Survivorship South West Cancer Network 14 November 2014.
Pathway for patients with suspected colorectal cancer
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Lung Cancer Pathway Dr Heather Harris - Consultant Radiologist
A systemwide approach to reducing long waiters
The BAHNO Head & Neck Cancer Surveillance Audit 2018
2018 National Mesothelioma Audit
Dr Rajayogeswaran Dr Mike Bradley
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Impact of 2019 Sarcoma Service specification for Bristol
Upper GI SSG Meeting Statistics
Early and locally advanced breast cancer
Pathway for patients with suspected Breast Cancer
Breast Multidisciplinary Team Meetings
28 Day Faster Diagnosis Standard
Living Well With and Beyond Cancer University Hospitals Bristol
Airedale NHS Foundation Trust
Living With & Beyond Cancer (Personalised Care): SWAG Colorectal CAG Update 5th June 2019 Catherine Neck, Macmillan Cancer Rehabilitation/ LWBC Lead On.
NHS Long Term Plan: Rapid Diagnostic Centres (RDC) The SWAG Approach
Urology cancer update for primary care
Presentation transcript:

Pathway for patients with suspected HPB Cancer Inter Provider Transfer Maximum Wait (Days) Pathway for patients with suspected HPB Cancer Provide information and psychological support throughout the patient journey Referral received in secondary care 10 Days Clinical history Physical examination Abdominal ultrasound Imaging of the chest First Seen Rapid specialist assessment & one stop diagnostic service 10 Holistic assessment and AHP rehabilitation consideration CT ERCP +/- biopsy Further diagnostic investigations as indicated Allocate HPB CNS 16-18 years old – refer to Paediatric Oncology (GNCC) for treatment and TYA MDT for discussion 19-24 years old – continue on tumour site specific pathway & refer to TYA MDT for discussion. Is HPB cancer still suspected? No Manage as appropriate and remove from cancer pathway Inform patient's GP of serious diagnosis See TYA pathway Yes Is patient to be managed locally, has tissue diagnosis been confirmed See HPB Rehabilitation Care Pathway liaise & involve healthcare professionals as required No Yes 15 Days Inter Provider Transfer Network Best Practice Specialist MDT to discuss treatment & rehabilitation plan Link with specialist MDT Consideration for clinical trial Local MDT discussion 25 6 Days CT MRI PET Scan EUS +/- biopsy Laparoscopy +/- biopsy ERCP +/- biopsy Staging Investigations as indicated Agree proposed treatment plan with patient Agree proposed treatment plan with patient Decision to treat 31 21 Days Surgical resection Best Supportive Care Radiotherapy Chemotherapy First Treatment 62 Specialist MDT to review treatment and rehabilitation plan plus consideration for clinical trials Is further treatment Required? Earliest Clinical Appropriate Date for commencement of subsequent treatment Yes ECAD date No Appropriate after care HPB Cancer Pathway